%0 Journal Article
%T Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers
%A Angelo Lauria
%A Antonio Ferronato
%A Antonio Penna
%A Antonio Tursi
%A Costantino Zampaletta
%A Cristina Ricciardelli
%A Francesco Luzza
%A Giacomo Forti
%A Giammarco Mocci
%A Giuseppe Pranzo
%A Ladislava Sebkova
%A Leonardo Allegretta
%A Marcello Picchio
%A Marilisa Franceschi
%A Nicola Della Valle
%A Roberto Faggiani
%A Roberto Lorenzetti
%A Sara Gallina
%A Simona Piergallini
%A Stefano Rodino
%A Tiziana Larussa
%A Walter Elisei
%J Archive of "Annals of Gastroenterology".
%D 2019
%R 10.20524/aog.2019.0377
%X The purpose of this study was to assess the efficacy and safety of biosimilar infliximab (IFX) CT-P13 in treating outpatients with inflammatory bowel disease (IBD) in Italian primary gastroenterology centers
%K Biosimilar
%K CT-P13
%K Crohn¡¯s disease
%K infliximab
%K ulcerative colitis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595921/